Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PI-273 |
Synonyms | |
Therapy Description |
PI-273 is a small molecule that binds to and inhibits PI4KII-alpha, potentially resulting in decreased proliferation and increased apoptosis of tumor cells, and reduced tumor growth (PMID: 28827373). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PI-273 | PI-273 is a small molecule that binds to and inhibits PI4KII-alpha, potentially resulting in decreased proliferation and increased apoptosis of tumor cells, and reduced tumor growth (PMID: 28827373). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
HRAS mutant | breast cancer | decreased response | PI-273 | Preclinical - Cell culture | Actionable | In a preclinical study, breast cancer cell lines harboring RAS mutations, including HRAS-mutant cell lines, demonstrated decreased sensitivity to growth inhibition by PI-273, in culture (PMID: 28827373). | 28827373 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|